Publications by authors named "Volant E"
Background: Current guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody-drug conjugates (ADCs): Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd), despite a similar payload. However, the effectiveness of one after another is unknown.
Methods: ADC-Low is a multicentre, retrospective study evaluating the efficacy of SG and T-DXd, one after another, with or without intermediary lines of chemotherapy, in patients with HER2-low MBC.
Article Synopsis
- This study focuses on the efficacy of tucatinib in combination with trastuzumab and capecitabine (TTC) for patients with ERBB2-positive metastatic breast cancer (MBC) who previously received trastuzumab-deruxtecan.
- A total of 101 patients were analyzed, primarily women with a median age of 56, who had undergone multiple prior treatments for metastatic disease, most of whom experienced disease progression during earlier therapies.
- Key findings indicate a median progression-free survival of 4.7 months and that a significant number (75.2%) of patients stopped TTC treatment due to disease progression during the follow-up period.